Nevro Reports Second Quarter 2019 Financial Results

REDWOOD CITY, Calif., Aug. 8, 2019 /PRNewswire/ -- Nevro Corp. NVRO, a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today reported financial results for the second quarter ended June 30, 2019.

Revenue for the second quarter of 2019 was $93.6 million, a 3% decrease compared to $96.1 million during the prior year period. U.S. revenue for the second quarter of 2019 was $78.1 million, a 2% decrease compared to $79.9 million in the prior year period. The year-over-year decrease in U.S. revenue was primarily driven by the impact of customer destocking associated with the Company's previously announced decision to alter its practice regarding certain high-volume product orders.  International revenue was $15.5 million compared to $16.2 million in the prior year period. This represents a 4% decrease on an as-reported basis and a 2% increase on a constant currency basis.

"Our second quarter 2019 financial results demonstrate sequential improvement across the board, as well as some encouraging early signs of progress in our commercial execution, including patient treatment activity with our customers.  In the U.S., we saw a year-over-year increase in patient trial procedures of 15%, while permanent implant procedures grew 10% over the prior year period," said D. Keith Grossman, Chairman, CEO and President. "I remain confident that as we continue to refine our commercial strategies and execution, prepare for our upcoming new product launches and drive interest in HF10 therapy, we will be well-positioned to enter our next phase of growth as we move into late 2019 and enter 2020."

Gross profit for the second quarter of 2019 was $63.9 million, a 6% decrease compared to $67.9 million in the prior year period. Gross margin was 68% in the second quarter of 2019 compared to 71% in the prior year period.

Operating expenses for the second quarter of 2019 were $90.5 million, a 19% increase compared to $76.1 million in the prior year period. The year-over-year increase in operating expenses was primarily driven by U.S. sales and marketing personnel costs, as well as clinical trial-related expenses. Legal expenses associated with patent litigation were $3.9 million for the second quarter of 2019, compared to $5.8 million in the prior year period.

Net loss from operations for the second quarter of 2019 was $26.6 million, compared to $8.2 million in the prior year period.

Cash, cash equivalents and short-term investments totaled $233.9 million as of June 30, 2019. Net cash used during the second quarter of 2019 was $5.7 million and $30.6 million for the six months ended June 30, 2019.

Full Year 2019 Financial Guidance

Nevro currently expects 2019 worldwide revenues to be in the $368 to $374 million range.  Gross margin is expected to be in the high 60's as a percent of revenue.

Webcast and Conference Call Information

Management will host a conference call today beginning at 1:30 p.m. PT / 4:30 p.m. ET.  Investors interested in listening to the conference call may do so by dialing (833) 286-5807 in the U.S. or (647) 689-4452 internationally, using Conference ID: 1694716.  In addition, a live webcast will be available on the "Investors" section of the company's website at www.nevro.com, as well as an archived recording.

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the SENZA® spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The SENZA® system is the only SCS system that delivers Nevro's proprietary HF10™ therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of Nevro.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements with respect to our business, capital resources, revenue projections, and our expectations for worldwide revenue in 2019, strategic initiatives and growth, reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including continuing adoption of, and interest in, Senza and Omnia in the U.S. and international markets. These forward-looking statements are based upon information that is currently available to us or our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including our ability to successfully commercialize our products; our ability to manufacture our products to meet demand; the level and availability of third-party payor reimbursement for our products; our ability to effectively manage our anticipated growth; our ability to protect our intellectual property rights and proprietary technologies; our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims. These factors, together with those that are described in greater detail in our quarterly report on Form 10-Q that we expect to file on August 8, 2019, as well as any reports that we may file with the SEC in the future, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements. Our results for the quarter ended June 30, 2019 are not necessarily indicative of our operating results for any future periods.

Investor Relations Contact:

Juliet Cunningham

Vice President, Investor Relations

650-208-3155

ir@nevro.com

Nevro Corp.

Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)







Three Months Ended





Six Months Ended







June 30,





June 30,







2019





2018





2019





2018







(unaudited)





(unaudited)



Revenue



$

93,571





$

96,080





$

175,719





$

183,715



Cost of revenue





29,628







28,159







58,567







53,793



Gross profit





63,943







67,921







117,152







129,922



Operating expenses:

































Research and development





14,930







11,416







29,065







22,501



Sales, general and administrative





75,573







64,706







156,901







131,324



Total operating expenses





90,503







76,122







185,966







153,825



Loss from operations





(26,560)







(8,201)







(68,814)







(23,903)



Other income (expense):

































Interest income (expense), net





(1,221)







(1,444)







(2,360)







(2,989)



Other income (expense), net





118







(592)







(225)







(715)



Loss before income taxes





(27,663)







(10,237)







(71,399)







(27,607)



Provision for income taxes





358







383







698







726



Net loss





(28,021)







(10,620)







(72,097)







(28,333)



Changes in foreign currency translation adjustment





(377)







(318)







(101)







259



Changes in unrealized gains (losses) on short-term investments





195







273







440







(78)



Net change in other comprehensive loss





(182)







(45)







339







181



Comprehensive Loss



$

(28,203)





$

(10,665)





$

(71,758)





$

(28,152)



Net loss per share, basic and diluted



$

(0.91)





$

(0.35)





$

(2.36)





$

(0.95)



Weighted average shares used to compute net loss per share, basic and diluted





30,677,567







30,028,985







30,521,463







29,933,164



 

Nevro Corp.

Consolidated Balance Sheets

(in thousands, except share and per share data)







June 30,





December 31,







2019





2018







(unaudited)











Assets

















Current assets

















Cash and cash equivalents



$

62,812





$

51,266



Short-term investments





171,119







213,281



Accounts receivable, net





67,052







80,656



Inventories, net





92,353







92,035



Prepaid expenses and other current assets





7,348







6,621



Total current assets





400,684







443,859



Property and equipment, net





11,983







12,801



Operating lease assets





23,153









Other assets





11,567







5,850



Restricted cash





606







606



Total assets



$

447,993





$

463,116



Liabilities and stockholders' equity

















Current liabilities

















Accounts payable



$

23,150





$

23,505



Accrued liabilities and other





43,073







38,909



Total current liabilities





66,223







62,414



Long-term debt





156,279







152,394



Long-term operating lease liabilities





22,187









Other long-term liabilities





1,762







2,825



Total liabilities





246,451







217,633



Stockholders' equity

















Common stock, $0.001 par value, 290,000,000 shares authorized, 30,870,626 and 30,263,536 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively





31







30



Additional paid-in capital





580,428







552,612



Accumulated other comprehensive loss





(738)







(1,077)



Accumulated deficit





(378,179)







(306,082)



Total stockholders' equity





201,542







245,483



Total liabilities and stockholders' equity



$

447,993





$

463,116



 

.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/nevro-reports-second-quarter-2019-financial-results-300898898.html

SOURCE Nevro Corp.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsPress ReleasesConference Call Announcements
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!